-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-6358 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-6358 in Colorectal Cancer Drug Details: JNJ-6358 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986360 in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986360 in Triple-Negative Breast Cancer (TNBC) Drug Details: BMS-986360 (CC-90001) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vepdegestrant in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vepdegestrant in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Vepdegestrant in Human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OMT-28 in Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMT-28 in Cardiomyopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.OMT-28 in CardiomyopathyDrug Details:OMT-28 is under development for the treatment of wet age related macular...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-222 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-222 in Relapsed Acute Myeloid Leukemia Drug Details: KITE-222...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BXQ-350 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BXQ-350 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BXQ-350 in Ovarian Cancer Drug Details:BXQ-350 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Larotrectinib Sulfate in Thyroid Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Larotrectinib Sulfate in Thyroid Cancer Drug Details: Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic agent. It...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AIV-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AIV-001 Drug Details AIV-001 is under development for the treatment of scar, low-risk basal...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AIV-007
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AIV-007 Drug Details AIV-007 is under development for the treatment of neovascular age-related macular...